The purpose of this IRB approved Humanitarian Use of a device is to allow patients to be treated with LDL-Apheresis, using the LIPOSORBER® LA-15 system. This device is approved for adult and pediatric patients with Focal Segmental Glomeruloslerosis as a Humanitarian Use Device. Its effectiveness has not been demonstrated.

This study will collect information about children who have rare types of lung disease to help us understand how better to diagnose and treat these patients. Information will be collected from participants' doctors about how different aspects of their disease and treatment. This will be compared to information from other such patients from other hospitals around the United States. By gathering information on many such patients, we hope to develop best practices for such patients. These may lead to new research studies, which we can invite participants in this study to consider as well.

About two in five people who are undergoing a kidney biopsy have diabetes. Diabetes is a common finding in people with kidney disease, but little is known about the specific ways in which diabetes affects kidney function. The purpose of this study is to gather two groups of patients with diabetes who undergo a kidney biopsy in order to create a source of information with genetic, blood, and urine samples available, by which researchers can study how diabetes affects kidney function.

The purpose of this research study is to evaluate the effects of HM15211 in people with NASH. This study will also evaluate study drug levels in your body and the time it takes your body to eliminate the drug (pharmacokinetics or PK) and what the study drug does to the body (pharmacodynamics or PD).

The purpose of this research study is to try and teach a computer program to assess how a dialysis vascular access fistula is maturing, when it could be ready to put needles in, or when it needs to be fixed to allow it to mature better; based on the electronic stethoscope recordings.

This study is comparing two approaches for monitoring and addressing symptoms among adult patients with kidney failure who are treated with hemodialysis. For the first approach patients use an electronic system twice a month to report their symptoms. The system sends alerts to their medical team at the dialysis clinic about the reported symptoms and gives suggestions about how to manage them. The system also provides reports that show patients and their medical team the reported symptoms over time. For the second approach patients complete a quality of life questionnaire that includes questions about symptoms once a year. The questionnaire does not have follow-up support like alerts, symptom management guidance, or reports. In addition, researchers will talk to patients, dialysis clinic personnel, and medical providers about their experiences using the electronic symptom monitoring system to learn about how to best use patient-reported outcome measures in dialysis care.

A multi-center open-label trial evaluating the efficacy and safety of daratumumab in treatment of patients with proliferative glomerulonephritis with monoclonal immunoglobulin deposits.

The purpose of this study is to compare clinical outcomes and health-related quality of life between an individualized hemodialysis prescription and conventional hemodialysis prescription in individuals requiring chronic hemodialysis who still have residual kidney function.

This study will compare 3 different ways to educate patients with advanced chronic kidney disease about hemodialysis vascular access.

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).